Viela reports detailed Phase II/III data for rare CNS disorder therapy

[cafead]

via Viela touted a potential dosing advantage and reiterated its plans to submit mid-year a BLA to FDA for inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD). The update came during a presentation at AAN on Tuesday in which the company reported detailed data from the Phase II/III N-MOmentum trial of the humanized mAb against CD19 in the indication.

article source